Breaking News, Trials & Filings

Immunomedics Begins Dosing in Pancreatic Cancer Trial

ADC increased overall survival in Ib trial

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Immunomedics has dosed the first patient in its Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan. Clivatuzumab tetraxetan contains a humanized, highly specific antibody that targets a mucin antigen found on pancreatic cancer cells, and is conjugated to a linker that facilitates complexing with radiometals.   The PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) is a double-blind, randomized study aimed to evaluate the safety and effi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters